BRAF and plasma cell myeloma: However, subsequent screening of larger cohorts of CLL and myeloma for both BRAFV600E and other BRAF hotspot mutations has identified a low incidence of predominantly subclonal V600E and non V600E BRAF mutations, usually associated with a poorer outcome [104,105,106,107,108].